Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CRISPR Therapeutics AG

Get SEC filing alerts via email and in your feed for CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

About CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Swiss biotech company specializing in developing gene editing medicines using CRISPR/Cas9 technology. Its core focus includes therapies for genetic blood disorders like sickle cell disease and beta thalassemia, as well as oncology, autoimmune diseases, and cardiovascular conditions. The company leverages ex vivo and in vivo gene editing approaches, partnering with industry leaders to create potentially curative, transformative treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CRISPR Therapeutics AG

1
1
CRISPR Therapeutics AG CRISPR Therapeutics Reports Q1 2026 Financial Results with Revenue Increase to $1.5 Million

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
CRISPR Therapeutics AG CRISPR Therapeutics Reports $581.6 Million Net Loss and Revenue Decline in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
CRISPR Therapeutics AG CRISPR Therapeutics Reports Q3 2025 Revenue Increase to $889,602 Amid Rising Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CRISPR Therapeutics AG CRISPR Therapeutics Reports Q2 2025 Revenue Surge to $892K, Net Loss of $208.5M

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CRISPR Therapeutics AG CRISPR Therapeutics Reports Q1 2025 Revenue Increase to $865,504 Amid Rising Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CRISPR Therapeutics AG CRISPR Therapeutics Reports $366.25 Million Net Loss for 2024, Decrease in Collaboration Revenue

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
CRISPR Therapeutics AG CRISPR Therapeutics Reports Mixed Q3 Results, Revenue Growth and Expense Reductions Offset by Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments